HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
PZt0ULsA6ZJFhkyU